The In-Vitro Diagnostics (IVD) segment has become one of the fastest-growing categories within the global medical devices industry, driven by rising chronic disease cases, increasing cancer screening programs, expanding infectious disease testing, and growing adoption of rapid diagnostic technologies.
IVD devices are used to analyze blood, urine, tissue, and other biological samples to detect diseases, monitor health conditions, and guide treatment decisions. These products include PCR systems, immunoassay analyzers, blood glucose monitors, hematology systems, rapid test kits, molecular diagnostic platforms, and point-of-care testing devices.
According to industry estimates, the global medical devices market was valued at more than USD 587 billion in 2025 and is projected to cross USD 1084 billion by 2035. The IVD segment alone represented approximately USD 110 billion–USD 125 billion of the global market, accounting for nearly 15%–18% of total medical device revenues.
Chronic Diseases Continue to Increase Diagnostic Testing Volumes
The rapid growth of IVD devices is closely linked to the increasing burden of chronic diseases worldwide.
The International Diabetes Federation estimates that nearly 589 million adults globally are living with diabetes in 2025, compared with around 537 million in 2021. This sharp increase is driving strong demand for blood glucose testing systems, continuous glucose monitoring devices, and laboratory diagnostic services.
Cancer cases are also rising significantly. According to the World Health Organization, more than 20 million new cancer cases and approximately 9.7 million cancer-related deaths were recorded globally in 2024. Early detection programs for breast cancer, cervical cancer, colorectal cancer, and lung cancer are increasing the use of molecular diagnostics and pathology testing systems.
Cardiovascular diseases remain the leading cause of death worldwide, responsible for nearly 17.9 million deaths annually. Hospitals and laboratories are expanding cardiac biomarker testing and preventive screening programs, further supporting diagnostic equipment demand.
Healthcare experts estimate that nearly 70% of medical decisions worldwide are influenced by laboratory diagnostic test results, making diagnostics one of the most critical components of modern healthcare systems.
Molecular Diagnostics and Point-of-Care Testing Drive Market Expansion
Within the IVD industry, molecular diagnostics and point-of-care testing are showing the strongest growth rates.
Molecular diagnostic systems can detect diseases through DNA and RNA analysis and are widely used for infectious diseases, oncology testing, genetic screening, and precision medicine. The molecular diagnostics market alone exceeded USD 25 billion globally in 2025 and continues to expand as hospitals adopt faster testing technologies.
Point-of-care diagnostics is another rapidly expanding category because patients increasingly prefer faster results outside centralized laboratories. These devices are now widely used in clinics, pharmacies, emergency departments, and home healthcare settings.
Rapid antigen tests, portable blood analyzers, handheld cardiac monitoring devices, and diabetes testing kits have become standard products in many healthcare systems.
The demand for decentralized testing increased sharply after the COVID-19 pandemic, during which billions of diagnostic tests were conducted worldwide. Governments across North America, Europe, China, and India subsequently increased investments in diagnostic infrastructure and laboratory capacity.
Roche, Abbott, and Siemens Continue to Lead Global IVD Revenues
Several multinational healthcare companies dominate the global IVD market through large-scale laboratory systems, molecular diagnostics, and rapid testing technologies.
Roche
Roche remains the global leader in in-vitro diagnostics. The company generated CHF 60.5 billion in total revenue in 2025, with diagnostics contributing approximately CHF 14 billion. Roche’s Cobas molecular testing systems and tissue diagnostics platforms are widely used across hospitals and laboratories worldwide.
Abbott Laboratories
Abbott has significantly expanded its diagnostics business through rapid testing systems and diabetes monitoring technologies. The company generated more than USD 40 billion in total annual revenue, while its diagnostics division remained one of its largest healthcare segments.
Abbott’s FreeStyle Libre diabetes monitoring system has become one of the world’s most widely used glucose monitoring platforms, serving millions of diabetes patients globally.
Siemens Healthineers
Siemens Healthineers continues to strengthen its diagnostics and imaging portfolio through laboratory automation systems, blood analyzers, and molecular testing platforms. The company reported revenue exceeding EUR 21 billion in fiscal 2025.
Danaher Corporation
Danaher owns several major diagnostic brands including Cepheid and Beckman Coulter. Cepheid became globally recognized during the COVID-19 pandemic for its rapid PCR testing systems used in hospitals and emergency settings.
Thermo Fisher Scientific
Thermo Fisher Scientific generated more than USD 42 billion in annual revenue and remains one of the leading suppliers of genomic sequencing systems, molecular diagnostics equipment, and laboratory instruments.
Asia-Pacific Emerging as the Fastest Growing Regional Market
North America currently dominates the global IVD market due to advanced healthcare infrastructure, high testing volumes, and strong reimbursement systems. However, Asia-Pacific is witnessing the fastest growth.
India and China are investing heavily in diagnostic laboratories, preventive healthcare programs, and healthcare digitization. Rising healthcare awareness, increasing middle-class healthcare spending, and expansion of private diagnostic chains are supporting market growth.
India’s diagnostics industry has expanded rapidly over the last decade, with companies such as Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare increasing laboratory networks across urban and semi-urban regions.
Key Industry Statistics
| Category | Statistics |
|---|---|
| Global medical devices market (2025) | Over USD 587 billion |
| Global IVD market size | USD 110–125 billion |
| IVD share in medical devices industry | Nearly 15%–18% |
| Adults living with diabetes globally | 589 million |
| Global cancer cases annually | Over 20 million |
| Annual cardiovascular disease deaths | 17.9 million |
| Share of medical decisions based on diagnostics | Nearly 70% |
| Major IVD companies | Roche, Abbott, Siemens Healthineers, Danaher, Thermo Fisher |
Future Outlook
The global healthcare industry is increasingly focusing on early disease detection, preventive healthcare, and faster clinical decision-making. This shift is expected to keep the IVD segment among the fastest-growing areas within medical devices over the next decade.
Growing testing volumes, rising chronic disease cases, expanding laboratory automation, and increasing demand for rapid diagnostics are likely to support continued market expansion across hospitals, laboratories, clinics, and home healthcare settings worldwide.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting delivers strategic insights across the medical devices market, including diagnostic devices, surgical equipment, imaging systems, wearable technologies, cardiovascular devices, and orthopedic implants. We help healthcare innovators track market trends, optimize product strategies, and drive growth through data-driven intelligence and industry expertise.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium